AKT1 and non-small cell lung carcinoma: Besides the anti-thrombotic features, it demonstrated anti-cancer activities in multiple in vitro studies, inhibiting various molecules and pathways such as receptor tyrosine kinases, PI3K-AKT pathway, and immune checkpoints PD-L1 and CD47, decreasing cell proliferation and inducing apoptosis in different cancers, including NSCLC and AML [128,129].